DAVID MAXWELL KLEINMAN, MD
Medical Practice in Rochester, NY
License number
New York 226139
Category
Medical Practice
Type
Ophthalmology
Address
Address
210 Crittenden Ave, Rochester, NY 14642
Phone
(585) 273-3937
(585) 276-0292 (Fax)
(585) 276-0292 (Fax)
Personal information
See more information about DAVID MAXWELL KLEINMAN at radaris.comName
Address
Phone
325 E 79Th St APT 15D, New York, NY 10075
3923 210Th St, Flushing, NY 11361
402 Centre Island Rd, Oyster Bay, NY 11771
420 E 61St St APT 18F, New York, NY 10065
4506 12Th Ave, Brooklyn, NY 11219
Professional information
See more information about DAVID MAXWELL KLEINMAN at trustoria.com
Chief Executive Officer At Eyeon Therapeutics, Inc.
Chief Executive Officer At Eyeon Therapeutics, Inc.
Position:
Associate Professor of Ophthalmology (part time) at Flaum Eye Institute at the University of Rochester, Chief Executive Officer at Eyeon Particle Sciences LLC, President and Chief Executive Officer at Eyeon Therapeutics, Inc., Consultant to health care companies and institutional investors at Self Employed
Location:
Rochester, New York Area
Industry:
Pharmaceuticals
Work:
Flaum Eye Institute at the University of Rochester
since Jun 2010
-
Associate Professor of Ophthalmology (part time)
Eyeon Particle Sciences LLC
since Jan 2009
-
Chief Executive Officer
Eyeon Therapeutics, Inc.
since Jun 2004
-
President and Chief Executive Officer
Self Employed
since Jan 2003
-
Consultant to health care companies and institutional investors
Flaum Eye Institute at the University of Rochester
Nov 2006 - May 2010
-
Assistant Professor of Ophthalmology (part time)
University of Colorado Health Sciences Center
Jul 2000 - Aug 2002
-
Assistant Professor of Ophthalmology
Denver Health
Jul 2000 - Aug 2002
-
Chief, Division of Ophthalmology
University of Toronto
Jul 1999 - Jun 2000
-
Fellow in Vitreoretinal Surgery
Himalayan Cataract Project
Jan 1999 - Jun 1999
-
Volunteer Surgeon
Project Orbis
Aug 1997 - Aug 1998
-
Staff Ophthalmologist
University of Colorado Health Sciences Center
Jul 1994 - Jun 1997
-
Resident in Ophthalmology
University of Washington
Jun 1993 - Jun 1994
-
Intern in Internal Medicine
Education:
University of Rochester - William E. Simon Graduate School of Business Administration 2004
MBA, Finance, Entrepreneurship, Health Sciences Management University of Colorado School of Medicine 1993
MD with honors Brown University 1988
BA, History
MBA, Finance, Entrepreneurship, Health Sciences Management University of Colorado School of Medicine 1993
MD with honors Brown University 1988
BA, History
Dr. David M Kleinman, Rochester NY - MD (Doctor of Medicine)
Dr. David M Kleinman, Rochester NY - MD (Doctor of Medicine)
Specialties:
Ophthalmology
Address:
Flaum Eye Institute
210 Crittenden Blvd SUITE 3, Rochester 14642
(585) 273-3937 (Phone)
210 Crittenden Blvd SUITE 3, Rochester 14642
(585) 273-3937 (Phone)
Certifications:
Ophthalmology, 2009
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Flaum Eye Institute
210 Crittenden Blvd SUITE 3, Rochester 14642
Rochester General Hospital
1425 Portland Ave, Rochester 14621
Strong Memorial Hospital
601 Elmwood Ave, Rochester 14642
210 Crittenden Blvd SUITE 3, Rochester 14642
Rochester General Hospital
1425 Portland Ave, Rochester 14621
Strong Memorial Hospital
601 Elmwood Ave, Rochester 14642
Education:
Medical School
University of Colorado At Denver
Graduated: 1993
U Wa Affil Hosps
U Co
U Toronto
University of Colorado At Denver
Graduated: 1993
U Wa Affil Hosps
U Co
U Toronto
David M Kleinman, Rochester NY
David M Kleinman, Rochester NY
Specialties:
Ophthalmology, Cardiology
Work:
University of Rochester
601 Elmwood Ave, Rochester, NY 14642
601 Elmwood Ave, Rochester, NY 14642
Education:
University of Colorado (1993)
Transscleral Delivery
Transscleral Delivery
US Patent:
2009032, Dec 31, 2009
Filed:
Aug 13, 2009
Appl. No.:
12/541085
Inventors:
Eugene R. COOPER - Berwyn PA, US
David M. Kleinman - Rochester NY, US
Thierry Nivaggioli - Atherton CA, US
Philippe J. M. Dor - Cupertino CA, US
Sreenivasu Mudumba - Union City CA, US
David M. Kleinman - Rochester NY, US
Thierry Nivaggioli - Atherton CA, US
Philippe J. M. Dor - Cupertino CA, US
Sreenivasu Mudumba - Union City CA, US
Assignee:
MacuSight, Inc. - Union City CA
International Classification:
A61K 9/00, A61K 31/436, A61P 27/02
US Classification:
424428, 514291, 424400, 424427
Abstract:
Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.
Formulations And Methods For Vascular Permeability-Related Diseases Or Conditions
Formulations And Methods For Vascular Permeability-Related Diseases Or Conditions
US Patent:
8222271, Jul 17, 2012
Filed:
Mar 23, 2007
Appl. No.:
11/726813
Inventors:
David M. Kleinman - Rochester NY, US
Thierry Nivaggioli - Atherton CA, US
Mary E. Gerritsen - San Mateo CA, US
David A. Weber - Danville CA, US
Thierry Nivaggioli - Atherton CA, US
Mary E. Gerritsen - San Mateo CA, US
David A. Weber - Danville CA, US
Assignee:
Santen Pharmaceutical Co., Ltd. - Osaka
International Classification:
A01N 43/42, A61K 31/44
US Classification:
514291
Abstract:
Described herein are formulations and methods for treating, inhibiting, preventing, delaying onset, or causing regression of a disease or condition relating to vascular permeability.
Transscleral Delivery
Transscleral Delivery
US Patent:
2009032, Dec 31, 2009
Filed:
Aug 14, 2009
Appl. No.:
12/541866
Inventors:
Eugene R. Cooper - Berwyn PA, US
David M. Kleinman - Rochester NY, US
Thierry Nivaggioli - Atherton CA, US
Philippe J. M. Dor - Cupertino CA, US
Sreenivasu Mudumba - Union City CA, US
David M. Kleinman - Rochester NY, US
Thierry Nivaggioli - Atherton CA, US
Philippe J. M. Dor - Cupertino CA, US
Sreenivasu Mudumba - Union City CA, US
Assignee:
MacuSight, Inc. - Union City CA
International Classification:
A61K 9/00, A61K 31/436, A61P 27/02
US Classification:
424428, 514291, 424400, 424427
Abstract:
Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.
Apparatus For The Treatment Of Cataract
Apparatus For The Treatment Of Cataract
US Patent:
8343214, Jan 1, 2013
Filed:
Oct 18, 2009
Appl. No.:
12/581152
Inventors:
David Maxwell Kleinman - Rochester NY, US
Assignee:
Cateract Innovations LLC - Rochester NY
International Classification:
A61F 2/16
US Classification:
623 41, 623 612, 623 656, 606107
Abstract:
A method and related apparatus to treat a cataract where the cataractous lens is pierced and the resulting opening is mechanically maintained using a lens system device such as a pinhole device, expandable tubular lens, a stent or similar small diameter device, some of which are capable of supporting a secondary intraocular lens. The resulting passageway or lumen created in the cataractous lens allows visible light to better reach the retina, thus improving vision. This lens system device that can be placed into an in situ cataract provides for a much simpler surgical technique and reduces related pre and post operative procedures and potential complications. Intraocular lenses may also be used in concert with this invention. The apparatus and technique can be applied to humans as well as animals.
Bi-Functional Co-Polymer Use For Opthalmic And Other Topical And Local Applications
Bi-Functional Co-Polymer Use For Opthalmic And Other Topical And Local Applications
US Patent:
2010022, Sep 9, 2010
Filed:
Feb 18, 2010
Appl. No.:
12/708329
Inventors:
Eugene R. Cooper - Berwyn PA, US
David M. Kleinman - Rochester NY, US
Andrew Loxley - Philadelphia PA, US
Mark Mitchnick - East Hampton NY, US
David M. Kleinman - Rochester NY, US
Andrew Loxley - Philadelphia PA, US
Mark Mitchnick - East Hampton NY, US
Assignee:
Eyeon Particle Sciences LLC - Rochester NY
International Classification:
A61K 9/51, A61K 47/48, A61K 9/00, A61K 31/74, A61P 27/02
US Classification:
424429, 424 7817, 424497
Abstract:
The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.
Formulations And Methods For Vascular Permeability-Related Diseases Or Conditions
Formulations And Methods For Vascular Permeability-Related Diseases Or Conditions
US Patent:
8486960, Jul 16, 2013
Filed:
Jun 21, 2012
Appl. No.:
13/530025
Inventors:
David M. Kleinman - Rochester NY, US
Thierry Nivaggioli - Atherton CA, US
Mary E. Gerritsen - San Mateo CA, US
David A. Weber - Danville CA, US
Thierry Nivaggioli - Atherton CA, US
Mary E. Gerritsen - San Mateo CA, US
David A. Weber - Danville CA, US
Assignee:
Santen Pharmaceutical Co., Ltd. - Osaka
International Classification:
A01N 43/42, A61K 31/44
US Classification:
514291
Abstract:
Described herein are formulations and methods for treating, inhibiting, preventing, delaying onset, or causing regression of a disease or condition relating to vascular permeability.
Ophthalmic Formulations Of Reversed Liquid Crystalline Phase Materials And Methods Of Using
Ophthalmic Formulations Of Reversed Liquid Crystalline Phase Materials And Methods Of Using
US Patent:
2011017, Jul 21, 2011
Filed:
Jul 9, 2010
Appl. No.:
12/833516
Inventors:
David Anderson - Ashland VA, US
Vince Conklin - Glen Allen VA, US
Benjamin Cameransi - Georgetown SC, US
David M. Kleinman - Rochester NY, US
Eugene R. Cooper - Berwyn PA, US
Vince Conklin - Glen Allen VA, US
Benjamin Cameransi - Georgetown SC, US
David M. Kleinman - Rochester NY, US
Eugene R. Cooper - Berwyn PA, US
International Classification:
A61K 9/10, A61K 9/00, A61K 38/13, A61K 39/00, A61K 31/573, A61K 31/445, A61K 39/395, A61K 31/685, A61K 31/355, A61K 9/14, A61P 37/06, A61P 29/00, A61P 27/02, B82Y 5/00
US Classification:
424484, 424400, 514 205, 4241841, 514180, 514330, 4241411, 514 78, 514458, 424489, 977906
Abstract:
The eye is effectively treated by providing it with formulations including uncoated cationically charged microparticles of reversed cubic phase or reversed hexagonal phase material. The treatment methods are effective; for a variety of diseases and conditions including dry eye. The structure, charge and components of the microparticles in dispersion, with or without an active ingredient, provide mucoadhesion, layering, protection and prolonged duration of ophthalmic action.